Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
| ▸ | MAPK7 | Q13164 | 9/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | PRLHR | P49683 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985525 | 0.88 | HSD11B1 (0.47) | MAPK7HSD11B1GRM5MGLL | |
| SCHEMBL4989547 | 0.85 | HPGD (0.49) | PDE4BPDE4DGRM5 | |
| SCHEMBL4989574 | 0.85 | MEN1 (0.48) | EPHX2 | |
| SCHEMBL4982979 | 0.84 | GRM5 (0.50) | GRM5 | |
| SCHEMBL4990817 | 0.82 | PKM (0.46) | GRM5 | |
| SCHEMBL4988057 | 0.82 | P2RX7 (0.45) | GRM5MGLL | |
| SCHEMBL4985624 | 0.81 | P2RX7 (0.49) | GRM5 | |
| SCHEMBL4983032 | 0.81 | ALDH1A1 (0.48) | MAPK7 | |
| SCHEMBL4987150 | 0.81 | SLC6A7 (0.44) | GRM5 | |
| SCHEMBL4991178 | 0.81 | P2RX7 (0.49) | HSD11B1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | EPHX2 569/4885MAPK7 512/4885HRH3 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.